Home › Colitis ulcerosa › New York › New York City
Colitis ulcerosa klinische studies in New York City, NY
23 studies voor Colitis ulcerosa zoeken deelnemers op locaties in en rond New York City (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
RekruterenFase 2
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RekruterenFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RekruterenFase 3
- New York Gastroenterology Associates ( Site 0253), New York
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RekruterenFase 2
- Pioneer Clinical Research NY, New York
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RekruterenFase 4
- New York Gastroenterology Associates, New York
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RekruterenFase 2
- Site 037, New York
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
RekruterenFase 3
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Icahn School of Medicine at Mount Sinai, New York
- Weill Cornell Medical College, New York
- en nog 2
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
RekruterenFase 2/3
- Columbia University Medical Center, New York
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RekruterenFase 3
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RekruterenFase 3
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
RekruterenFase 4
- NYU Langone Health, New York
- Weill Cornell Medical College- New York Presbyterian Hospital, New York
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RekruterenFase 3
- Weill Cornell Medicine - NewYork-Presbyterian Hospital - Site Number: 8400040, New York
- New York Gastroenterology Associates - Site Number: 8400009, New York
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
RekruterenFase 3
- New York Gastroenterology Associates, New York
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
RekruterenFase 2
- Fink Children's Ambulatory Care Center, New York
- Kimmel Pavilion - NYU Langone, New York
- NYU Grossman School of Medicine, New York
- en nog 4
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
RekruterenFase 2
- Columbia University Medical Center, New York
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RekruterenFase 3
- Manhattan Clinical Research, LLC - Site Number: 8400069, New York
- NYU Langone Health - Site Number: 8400091, New York
- Weill Cornell Medical College - NewYork-Presbyterian Hospital - Site Number: 8400040, New York
- en nog 2
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Rekruteren
- NYU Langone Health, New York
- Cornell University, New York
BOOM-IBD2 Pivotal Clinical Trial
Rekruteren
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RekruterenObservatieonderzoek
- New York University, New York
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
RekruterenObservatieonderzoek
- NYU Langone Health, New York
- Lenox Hill Hospital, Northwell Health, New York
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RekruterenFase 3
- New York Presbyterian Hospital, New York
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RekruterenFase 2
- Mirador Therapeutics Selected Site, New York
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RekruterenObservatieonderzoek
- New York University, New York
Colitis ulcerosa studies in andere steden
- Orlando, FL22 studies
- Miami, FL21 studies
- Houston, TX17 studies
- San Antonio, TX16 studies
- Tyler, TX15 studies
- Tacoma, WA15 studies
- Chicago, IL15 studies
- San Diego, CA15 studies
- Colorado Springs, CO14 studies
- Los Angeles, CA13 studies
- St. Louis, MO13 studies
- Washington, DC12 studies
Andere studies in New York City
- Borstkanker136 studies
- Niet-kleincellige longkanker121 studies
- Kanker (alle vormen)109 studies
- Prostaatkanker103 studies
- Metastatische kanker93 studies
- Colorectale kanker78 studies
- Eierstokkanker69 studies
- Longkanker60 studies
- Multipel myeloom60 studies
- Aldermeesklierkanker60 studies
- Endometriumkanker52 studies
- Acute myeloïde leukemie51 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.